-
2025-523612-37-00
3
2026-01-23
Parkinson's Disease and Apathy
-
2024-515023-11-00
5
2026-01-22
Metastatic Clear Cell Renal Cell Carcinoma
-
2025-522857-20-00
9
2026-01-22
Severe, treatment refractory primary Sjögren’s disease (pSjD)
-
2023-507879-21-00
4
2026-01-19
AML and MDS undergoing allogeneic Transplantation
-
2024-516471-33-00
4
2026-01-19
Alport Syndrome
-
2025-522683-32-00
5
2026-01-15
Early-Stage Parkinson’s Disease (PD)
-
2025-522631-34-00
5
2026-01-14
Osteoarthritis
-
2025-523115-11-00
1
2026-01-14
Phase I study in healthy participants. Intended indication: atopic der
-
2024-518281-27-00
7
2026-01-09
Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer
-
2024-517421-12-00
3
2026-01-07
Osteoarthritis
-
2025-520518-79-00
4
2026-01-06
Atrial Fibrillation
-
2024-511508-18-00
9
2026-01-05
Chronic graft versus host disease.
-
2025-521144-38-00
4
2025-12-23
Primary Central Nervous System Lymphoma
-
2024-512503-39-00
6
2025-12-19
Arm A (AML): Newly diagnosed de novo Acute myeloid leukemia (AML) or M
-
2025-521003-52-00
9
2025-12-19
HER2 Expressing Advanced Breast Cancer
-
2025-521661-27-00
10
2025-12-19
Primary Membranous Nephropathy
-
2022-500676-59-00
4
2025-12-18
EBV-positive nasopharyngeal carcinoma
-
2024-512298-28-00
11
2025-12-18
Neovascular age-related macular degeneration
-
2025-522718-22-00
4
2025-12-16
Gastroesophageal Adenocarcinoma
-
2025-523009-14-00
4
2025-12-16
Bronchiectasis with chronic pseudomonas aeruginosa colonization
-
2025-521735-36-00
7
2025-12-15
Relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL) or chronic
-
2025-521738-27-00
4
2025-12-15
Recurrent Metastatic Head and Neck Cancer
-
2024-518465-10-00
4
2025-12-12
Multiple Autoimmune Glomerular Diseases
-
2024-519960-42-00
4
2025-12-11
PIK3CA-Related Overgrowth Spectrum (PROS)